The U.S. Food and Drug Administration (FDA) issued an update on Dec. 6 about its ongoing recall of heart and blood pressure medication due to impurities that could cause cancer.
It said Mylan Pharmaceuticals “is expanding its voluntary recall to include all lots of non-expired valsartan-containing products due to trace amounts of N-Nitrosodiethylamine (NDEA) in the valsartan active pharmaceutical ingredient (API) manufactured by” by Mylan Inc.
